Cancer Epigenetics Training (CET) Program

项目总结 这项提议寻求在Van Andel开发一个专门的癌症表观遗传学培训(CET)计划 研究所(VARI)每年培训两名新的博士后研究员，每名为期三年。目标是 CET的目的是培养10名博士后研究员，以成为独立的学术和行业研究人员 癌症表观遗传学领域的领导者。CET计划将建立在表观遗传学中心的基础上 是由彼得·琼斯博士于2014年创立的。已经成长为世界级的，国际上的 公认的基础和转化表遗传学研究的卓越中心。为了启动CET计划， 我们已经组建了一个由9名导师和6名共同导师组成的团队，他们每年总共拥有约570万美元的资金 并具有高度互补性和跨学科的癌症和表观遗传学专业知识。CET教师包括 几位表观遗传学先驱；美国国家科学院的两名成员；范安德尔研究所 对抗癌症表观遗传学梦想团队(VAI-SU2C)；癌症基因组图谱(TCGA)的两名负责人 项目；以及职业生涯各个阶段的导师/共同导师。学员将能够学习基础知识和翻译知识 癌症生物学研究项目；肿瘤发生、细胞发育和分化；机制 管理DNA甲基化和染色质调节；表观基因组学和高级工具开发； 和EWAS；跨代遗传；结构生物学；新陈代谢；表观遗传疗法。大学英语四级考试 该计划由一个专门的咨询委员会监督，该委员会由来自学术界、 工业和临床职业。我们制定了有针对性的多元化和招聘计划，以增加 符合T32条件的人才库规模，并吸引和留住代表不足的群体中的个人。一经接受， 每个学员都被分配了一个单独的开发团队(IDT)来指导、指导和指导学员 通过职业发展的科学和非科学两个维度。教员和CET实习生是 由博士后事务办公室支持，该办公室由博士后级别的生物医学职业指导 开发专业人士。每个学员都必须完成科学和技术课程的综合课程 职业发展培训。T32学员的主要成果和里程碑包括年度研讨会 (内部和外部)；至少一学期的教学或指导经验；一位第一作者 出版物；以及至少一份已提交的F32(或同等)和K99/R00申请。培训 要求和期望在经过审查的个人发展计划(IDP)中正式确定 咨询委员会每年举行一次会议。与研究相关的个性化培训没有在 CET培训项目由VARI提供。大学英语四级考试将通过入学、年度、 离职，以及校友评估。在CET提供的最好的师资、资源和指导下， 博士后研究员将拥有全面的、多学科的技能、视角和基础 从中建立他们在癌症表观遗传学方面的独立研究生涯。

PROJECT SUMMARY This proposal seeks to develop a dedicated Cancer Epigenetics Training (CET) program at Van Andel Research Institute (VARI) to train two new postdoctoral fellows per year for three years each. The objective of the CET is to prepare 10 postdoctoral fellows to become independent academic and industry research leaders in the field of cancer epigenetics. The CET program will build upon the Center for Epigenetics that was established in 2014 by Peter Jones, Ph.D., D.Sc. (hon) and has grown into a world-class, internationally recognized center of excellence for basic and translational epigenetics research. To launch the CET program, we have assembled a team of 9 mentors and 6 co-mentors who collectively hold ~$5.7M of funding per year and have highly complementary and interdisciplinary cancer and epigenetics expertise. CET faculty include several epigenetics pioneers; two members of the National Academy of Sciences; the Van Andel Institute Stand Up to Cancer Epigenetics Dream Team (VAI-SU2C); two leaders of The Cancer Genome Atlas (TCGA) project; and mentors/co-mentors from all career stages. Trainees will be able to pursue basic and translational research projects in cancer biology; tumorigenesis, cellular development and differentiation; mechanisms governing DNA methylation and chromatin regulation; epigenomics and advanced tool development; GWAS and EWAS; transgenerational inheritance; structural biology; metabolism; and epigenetic therapies. The CET program is overseen by a dedicated Advisory Committee composed of domain-level experts from academic, industrial, and clinical careers. We have developed a targeted diversity and recruitment plan to increase the T32-eligible pool size and attract and retain individuals from underrepresented groups. Upon acceptance, each Trainee is assigned an Individual Development Team (IDT) to coach, mentor, and guide the Trainee through the scientific and non-scientific dimensions of career development. The faculty and CET Trainees are supported by a dedicated Office of Postdoctoral Affairs that is directed by a PhD-level biomedical career development professional. Each Trainee is required to complete a comprehensive curriculum of scientific and professional development training. Key deliverables and milestones for T32 Trainees include annual seminars (internal and external); at least one semester of teaching or mentoring experience; one first-authored publication; and at least one submitted F32 (or equivalent) and K99/R00 application. The training requirements and expectations are formalized within Individual Development Plans (IDPs) that are reviewed annually by the Advisory Committee. Research-related, individualized training not otherwise defined in the CET training program is provided by VARI. The CET will be rigorously evaluated through entrance, annual, exit, and alumni assessments. With the superlative faculty, resources, and guidance afforded by the CET, postdoctoral fellows will emerge with a comprehensive, multi-disciplinary skill set, perspective, and foundation from which to establish their independent research careers in cancer epigenetics.